Literature DB >> 16527512

Oral candidosis in patients with advanced cancer.

Andrew N Davies1, Susan R Brailsford, David Beighton.   

Abstract

The objectives of the study were to determine the epidemiology, aetiology, clinical features and microbiological aspects of oral candidosis in a cohort of cancer patients receiving specialist palliative care. One hundred and twenty patients participated in the study. Seventy-nine (66%) of the patients had microbiological evidence of oral yeast carriage, whilst 36 (30%) of the patients had combined clinical and microbiological evidence of oral candidosis. Oral candidosis was associated with a poor performance status, the presence of xerostomia, and the presence of dentures; oral candidosis was not associated with the use of oral/parenteral antibiotics, or the use of oral/parenteral corticosteroids. Candida albicans was the predominant organism isolated from the oral swabs of patients with oral candidosis. However, non-C. albicans species were the predominant organism in 25% cases, and a contributing organism in a further 19% cases.

Entities:  

Mesh:

Year:  2006        PMID: 16527512     DOI: 10.1016/j.oraloncology.2005.11.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  25 in total

1.  Oral health is an important issue in end-of-life cancer care.

Authors:  Petter Wilberg; Marianne J Hjermstad; Stig Ottesen; Bente B Herlofson
Journal:  Support Care Cancer       Date:  2012-03-21       Impact factor: 3.603

2.  Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis.

Authors:  Joanna Boros-Majewska; Natalia Salewska; Edward Borowski; Sławomir Milewski; Sladjana Malic; Xiao-Qing Wei; Anthony J Hayes; Melanie J Wilson; David W Williams
Journal:  Med Microbiol Immunol       Date:  2014-06-13       Impact factor: 3.402

3.  Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance.

Authors:  M A Ghannoum; J Herbert; N Isham
Journal:  Mycoses       Date:  2010-03-04       Impact factor: 4.377

4.  Associations between oral complications and days to death in palliative care patients.

Authors:  K Matsuo; R Watanabe; D Kanamori; K Nakagawa; W Fujii; Y Urasaki; M Murai; N Mori; T Higashiguchi
Journal:  Support Care Cancer       Date:  2015-05-12       Impact factor: 3.603

Review 5.  Salivary gland stem cells: A review of development, regeneration and cancer.

Authors:  Elaine Emmerson; Sarah M Knox
Journal:  Genesis       Date:  2018-05-04       Impact factor: 2.487

6.  Oral health conditions affect functional and social activities of terminally ill cancer patients.

Authors:  D J Fischer; J B Epstein; Y Yao; D J Wilkie
Journal:  Support Care Cancer       Date:  2014-03       Impact factor: 3.603

7.  Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy.

Authors:  Ana Mañas; Laura Cerezo; Alejandro de la Torre; Mariola García; Héctor Alburquerque; Blanca Ludeña; Ana Ruiz; Ana Pérez; Ana Escribano; Aurea Manso; Luis Alberto Glaria
Journal:  Clin Transl Oncol       Date:  2012-09-08       Impact factor: 3.405

8.  Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China.

Authors:  Haiyan Sun; Yong Chen; Xuan Zou; Huan Li; Xiuyun Yin; Haifeng Qin; Rongrui Liu; Changlin Yu; Qihong Li; Kaitao Yu; Xuelin Han; Jingcai Zou; Cheng Ge; Li Han
Journal:  Clin Oral Investig       Date:  2015-07-30       Impact factor: 3.573

9.  Patients with long-term oral carriage harbor high-persister mutants of Candida albicans.

Authors:  Michael D Lafleur; Qingguo Qi; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

Review 10.  Fungal PDR transporters: Phylogeny, topology, motifs and function.

Authors:  Erwin Lamping; Philippe V Baret; Ann R Holmes; Brian C Monk; Andre Goffeau; Richard D Cannon
Journal:  Fungal Genet Biol       Date:  2009-10-24       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.